$ILMN

Davies Scott M sold $98K of ILMN

Davies Scott M (Chief Legal Officer) sold 615 shares of ILLUMINA, INC. (ILMN) at $160.00 on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davies Scott M
Published Jun 1, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:58 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale details (615 shares at $160) and that it was executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and modest transaction size reduce expected market impact.

03

What to watch

The article provides no context on whether this sale is part of a larger series, nor any concurrent company-specific news, limiting inference beyond the transaction itself.

Relevance 2/10Novelty 3/10Timing: filed June 1, transaction dated May 29

Background

The article is a SEC Form 4 insider transaction disclosure for Illumina, Inc. (ILMN).

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina disclosed a Form 4 showing Chief Legal Officer Davies Scott M sold 615 shares at $160 on May 29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any reaction is likely muted.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed size is modest relative to typical large-cap trading flows.

Market effects

No clear read-through to the biotech tools or sequencing equipment sector from a single routine 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may still watch for follow-on sales or other negative disclosures.

Key entities

  • Illumina, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Davies Scott M

    Chief Legal Officer who sold shares under a 10b5-1 plan.

Related articles

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.

$ILMNMedAI 8/10

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full

Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.

$ILMNHigh

ILLUMINA, INC. (ILMN): Results of Operations and Financial Condition

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.